Drug-drug interactions and adverse drug reactions: Separating the wheat from the chaff

Wiener Klinische Wochenschrift

Volumn 122, Issue 3-4, 2010, Pages 62-64

  Pirmohamed, Munir ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Adverse drug reaction; Drug drug interactions; Polypharmacy

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LITHIUM; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; SPIRONOLACTONE; TRIMETHOPRIM; WARFARIN;

ADD ON THERAPY; ADVERSE DRUG REACTION; CAUSE OF DEATH; CLASSIFICATION; COMORBIDITY; DEMOGRAPHY; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG INHIBITION; DRUG INTERACTION; DRUG METABOLISM; DRUG POTENTIATION; ELECTRONIC PRESCRIBING; EMERGENCY WARD; EVIDENCE BASED PRACTICE; FATALITY; HARM REDUCTION; HEALTH CARE; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITAL PATIENT; HOSPITALIZATION; MORBIDITY; OUTPATIENT; PRESCRIPTION; PRIMARY MEDICAL CARE; RISK FACTOR; RISK REDUCTION; SHORT SURVEY; UNITED KINGDOM; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DRUG INCOMPATIBILITY; DRUG INTERACTIONS; DRUG TOXICITY; EUROPE;

EID: 77952485458     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-010-1309-1     Document Type: Short Survey

References (25)

1. Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a metaanalysis of prospective studies. Jama 279: 1200-1205
2. Pirmohamed M, James S, Meakin S, et al (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. Bmj 329: 15-19 (Pubitemid 38869995)
3. Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M (2009) Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patientepisodes. PLoS One 4: e4439
4. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL (2006) National surveillance of emergency department visits for outpatient adverse drug events. JAMA 296: 1858-1866
5. Gandhi TK, Weingart SN, Borus J, et al (2003) Adverse drug events in ambulatory care. N Engl J Med 348: 1556-1564
6. Moore TJ, Cohen MR, Furberg CD (2007) Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med 167: 1752-1759
7. Ferner RE, Aronson JK (2010) EIDOS: a mechanistic classification of adverse drug effects. Drug Saf 33: 15-23
8. Aronson JK, Ferner RE (2003) Joining the DoTS: new approach to classifying adverse drug reactions. BMJ 327: 1222-1225
9. Agrawal A, Aronson JK, Britten N, et al (2009) Medication errors: problems and recommendations from a consensus meeting. Br J Clin Pharmacol 67: 592-598
10. Fokter N, Mozina M, Brvar M (2010) Potential drug-drug interactions and admissions due to drug-drug interactions in patients treated in medical departments. Wien Klin Wochenschr 122: 81-88
11. Spencer FA, Lessard D, Yarzebski J, Gore JM, Goldberg RJ (2005) Decade-long changes in the use of combination evidence-based medical therapy at discharge for patients surviving acute myocardial infarction. Am Heart J 150: 838-844
12. Floyd KC, Yarzebski J, Spencer FA, et al (2009) A 30-year perspective (1975-2005) into the changing landscape of patients hospitalized with initial acute myocardial infarction: Worcester Heart Attack Study. Circ Cardiovasc Qual Outcomes 2: 88-95
13. McKinnon JE, Mellors JW, Swindells S (2009) Simplification strategies to reduce antiretroviral drug exposure: progress and prospects. Antivir Ther 14: 1-12
14. Egger SS, Ratz Bravo AE, Hess L, Schlienger RG, Krahenbuhl S (2007) Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins. Drugs Aging 24: 429-440
15. Davies EC, Green CF, Mottram DR, Pirmohamed M (2007) Adverse drug reactions in hospitals: a narrative review. Curr Drug Saf 2: 79-87
16. Pitt B, Zannad F, Remme WJ, et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709-717
17. Juurlink DN, Mamdani MM, Lee DS, et al (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351: 543-551
18. McMurray JJ, O'Meara E (2004) Treatment of heart failure with spironolactone - trial and tribulations. N Engl J Med 351: 526-528
19. Lau HS, Florax C, Porsius AJ, De Boer A (2000) The completeness of medication histories in hospital medical records of patients admitted to general internal medicine wards. Br J Clin Pharmacol 49: 597-603
20. Kaushal R, Shojania KG, Bates DW (2003) Effects of computerized physician order entry and clinical decision support systems on medication safety: a systematic review. Arch Intern Med 163: 1409-1416
21. Constable S, Ham A, Pirmohamed M (2007) Herbal medicines and acute medical emergency admissions to hospital. Br J Clin Pharmaco. 63: 247-248
22. Bellosta S, Paoletti R, Corsini A (2004) Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 109: III50-III57
23. Seidling HM, Storch CH, Bertsche T, et al (2009) Successful strategy to improve the specificity of electronic statin-drug interaction alerts. Eur J Clin Pharmacol 65: 1149-1157
24. Pirmohamed M, Ferner RE (2003) Monitoring drug treatment - criteria used for screening tests should apply to monitoring. Br Med J 327: 1179-1181
25. Norgard NB, Mathews KD, Wall GC (2009) Drug-drug interaction between clopidogrel and the proton pump inhibitors. Ann Pharmacother 43: 1266-1274